Published in Brain Pathol on April 01, 2004
Genetic pathways to primary and secondary glioblastoma. Am J Pathol (2007) 9.27
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev (2010) 3.99
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
Heterogeneity maintenance in glioblastoma: a social network. Cancer Res (2011) 2.66
EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell (2013) 2.28
Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia (2010) 2.21
Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci U S A (2009) 2.11
Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer (2014) 2.10
Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer (2007) 1.67
EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway. Oncogene (2011) 1.42
The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med (2005) 1.33
The interface between glial progenitors and gliomas. Acta Neuropathol (2008) 1.33
Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas. Clin Cancer Res (2008) 1.25
A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens. Cancer Res (2010) 1.20
Oncogenic extracellular vesicles in brain tumor progression. Front Physiol (2012) 1.15
EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathol (2013) 1.13
Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Front Pharmacol (2013) 1.09
Molecular pathogenesis of pediatric astrocytic tumors. Neuro Oncol (2007) 1.07
Biology, genetics and imaging of glial cell tumours. Br J Radiol (2011) 1.00
Stem cells as drug delivery methods: application of stem cell secretome for regeneration. Adv Drug Deliv Rev (2014) 0.99
Leptin and its receptor are overexpressed in brain tumors and correlate with the degree of malignancy. Brain Pathol (2009) 0.99
CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. Sci Rep (2015) 0.98
EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin Invest (2014) 0.97
Aberrant signaling pathways in glioma. Cancers (Basel) (2011) 0.96
Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. Nat Neurosci (2016) 0.95
Opposing effect of EGFRWT on EGFRvIII-mediated NF-κB activation with RIP1 as a cell death switch. Cell Rep (2013) 0.94
Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates. Acta Neuropathol (2013) 0.90
An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII. Oncogene (2013) 0.89
EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma. Oncogene (2013) 0.86
EGFR gene overexpression retained in an invasive xenograft model by solid orthotopic transplantation of human glioblastoma multiforme into nude mice. Cancer Invest (2011) 0.82
Specific and sensitive hydrolysis probe-based real-time PCR detection of epidermal growth factor receptor variant III in oral squamous cell carcinoma. PLoS One (2012) 0.82
Molecular pathologic diagnosis of epidermal growth factor receptor. Neuro Oncol (2014) 0.80
Evolving Molecular Genetics of Glioblastoma. Chin Med J (Engl) (2016) 0.79
Targeted therapy in the treatment of malignant gliomas. Onco Targets Ther (2009) 0.78
Extracellular Vesicles in Brain Tumor Progression. Cell Mol Neurobiol (2016) 0.76
How cancer cells dictate their microenvironment: present roles of extracellular vesicles. Cell Mol Life Sci (2016) 0.75
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
Genetic pathways to primary and secondary glioblastoma. Am J Pathol (2007) 9.27
Genetic pathways to glioblastoma: a population-based study. Cancer Res (2004) 8.87
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol (2009) 6.43
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol (2005) 6.16
Epidemiology and etiology of gliomas. Acta Neuropathol (2005) 6.14
The definition of primary and secondary glioblastoma. Clin Cancer Res (2012) 3.84
Integrity of the conduct of the IARC monographs program. Int J Occup Environ Health (2003) 3.55
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res (2009) 2.95
Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci (2009) 2.75
Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol (2006) 2.51
Age as a predictive factor in glioblastomas: population-based study. Neuroepidemiology (2009) 2.44
Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol (2004) 2.15
Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res (2003) 2.08
Anaplastic ependymoma with ependymoblastic multilayered rosettes. Hum Pathol (2013) 1.97
The science and practice of carcinogen identification and evaluation. Environ Health Perspect (2004) 1.89
Haploinsufficiency of CSF-1R and clinicopathologic characterization in patients with HDLS. Neurology (2013) 1.81
Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study. Neuroepidemiology (2008) 1.68
Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer (2003) 1.67
A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. J Neurosurg (2003) 1.60
APC mutations are infrequent but present in human lung cancer. Cancer Lett (2004) 1.57
alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. Am J Pathol (2004) 1.53
Molecular classification of low-grade diffuse gliomas. Am J Pathol (2010) 1.51
TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol (2013) 1.51
alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. Acta Neuropathol (2004) 1.43
Tau-positive glial cytoplasmic granules in multiple system atrophy. Neuropathology (2010) 1.42
Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol (2001) 1.38
PTEN methylation and expression in glioblastomas. Acta Neuropathol (2003) 1.31
Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(-/-) mice. Am J Pathol (2003) 1.28
Molecular pathogenesis of astrocytic tumours. J Neurooncol (2004) 1.24
PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol (2007) 1.23
Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res (2002) 1.23
Synergistic role of Ku80 and poly(ADP-ribose) polymerase in suppressing chromosomal aberrations and liver cancer formation. Cancer Res (2002) 1.20
Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol (2011) 1.18
TP53 promoter methylation in human gliomas. Acta Neuropathol (2005) 1.17
Schwannoma of the breast: report of a case. Surg Today (2005) 1.16
Primary bilateral adrenal diffuse large B-cell lymphoma demonstrating adrenal failure. Intern Med (2010) 1.14
AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene (2003) 1.13
Altered expression of immune defense genes in pilocytic astrocytomas. J Neuropathol Exp Neurol (2005) 1.11
Genetic alterations in the PI3K pathway in prostate cancer. Anticancer Res (2009) 1.09
Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int J Cancer (2011) 1.08
Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results. PLoS One (2013) 1.04
Analysis of chromosome 19q13.42 amplification in embryonal brain tumors with ependymoblastic multilayered rosettes. Brain Pathol (2012) 1.02
Stratification of medulloblastoma on the basis of histopathological grading. Acta Neuropathol (2006) 1.01
Alterations in the RB1 pathway in low-grade diffuse gliomas lacking common genetic alterations. Brain Pathol (2011) 1.00
Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res (2002) 0.99
TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. J Clin Pathol (2011) 0.99
Nephrotic syndrome caused by immune-mediated acquired LCAT deficiency. J Am Soc Nephrol (2013) 0.99
Genetic alterations in microRNAs in medulloblastomas. Brain Pathol (2011) 0.98
Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol (2009) 0.97
Genetic alterations in primary glioblastomas in Japan. J Neuropathol Exp Neurol (2006) 0.97
Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histogenesis and biology. Glia (2009) 0.96
Alterations of BCCIP, a BRCA2 interacting protein, in astrocytomas. BMC Cancer (2009) 0.95
Genetic profiling of CNS tumors extends histological classification. Acta Neuropathol (2010) 0.94
CXCL17 expression by tumor cells recruits CD11b+Gr1 high F4/80- cells and promotes tumor progression. PLoS One (2012) 0.94
Intratumoral patterns of genomic imbalance in glioblastomas. Brain Pathol (2010) 0.94
MicroRNA-21 suppression impedes medulloblastoma cell migration. Eur J Cancer (2011) 0.94
High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein. Brain Tumor Pathol (2011) 0.93
Frequent BRAF gain in low-grade diffuse gliomas with 1p/19q loss. Brain Pathol (2012) 0.92
Oxidative and nitrative stress caused by subcutaneous implantation of a foreign body accelerates sarcoma development in Trp53+/- mice. Carcinogenesis (2006) 0.92
Mutations in the Nijmegen breakage syndrome gene in medulloblastomas. Clin Cancer Res (2008) 0.91
Gene expression profiling and subgroup identification of oligodendrogliomas. Oncogene (2004) 0.89
Congenital glioblastoma: a clinicopathologic and genetic analysis. Brain Pathol (2007) 0.88
Transcriptional factors for epithelial-mesenchymal transition are associated with mesenchymal differentiation in gliosarcoma. Brain Pathol (2012) 0.88
Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology. Acta Neuropathol (2006) 0.88
A distinct pattern of Olig2-positive cellular distribution in papillary glioneuronal tumors: a manifestation of the oligodendroglial phenotype? Acta Neuropathol (2005) 0.87
Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas. Brain Pathol (2008) 0.87
The glial response to CNS HIV infection includes p53 activation and increased expression of p53 target genes. J Neuroimmune Pharmacol (2007) 0.87
Methylation of the p73 gene in gliomas. Acta Neuropathol (2002) 0.87
Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study. Neuropathology (2011) 0.86
Enteropathy-type T-cell lymphoma that was pathologically diagnosed as celiac disease. Intern Med (2007) 0.86
Granular cell astrocytomas show a high frequency of allelic loss but are not a genetically defined subset. Brain Pathol (2003) 0.86
MiR-22 is frequently downregulated in medulloblastomas and inhibits cell proliferation via the novel target PAPST1. Brain Pathol (2014) 0.85
KIAA1549-BRAF fusions and IDH mutations can coexist in diffuse gliomas of adults. Brain Pathol (2012) 0.85
Whole genome amplification for array comparative genomic hybridization using DNA extracted from formalin-fixed, paraffin-embedded histological sections. J Mol Diagn (2009) 0.85
Enhancement of in vitro human tubulogenesis by endothelial cell-derived factors: implications for in vivo tubular regeneration after injury. Am J Physiol Renal Physiol (2011) 0.83
Antiserum against human glucose transporter 5 is highly specific for microglia among cells of the mononuclear phagocyte system. Neurosci Lett (2003) 0.83